Lv11
30 积分 2024-12-27 加入
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
4小时前
已完结
Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay
5天前
已完结
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
6天前
已完结
Internalization of the vedolizumab/α4β7 complex and kinetics of restoring functional activity
7天前
已完结
MAIT cells monitor intestinal dysbiosis and contribute to host protection during colitis
8天前
已完结
P1114 Engineering and Development of a Novel Bispecific Antibody Targeting IL-23 and TL1A
11天前
已完结
Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling
19天前
已完结
Internalization of the vedolizumab/α4β7 complex and kinetics of restoring functional activity
1个月前
已完结
Sa2025 Etrolizumab-Mediated Ex Vivo Modulation of Beta7 Cell Surface Receptors in Nonhuman Primate and Human Peripheral Blood Supports the Proposed Mechanism of Action
1个月前
已完结
Generation of Mutated Variants of the Human Form of the MHC Class I-related Receptor, FcRn, with Increased Affinity for Mouse Immunoglobulin G
2个月前
已完结
皖公网安备34019202002308
